Ovid Therapeutics (OVID) EBT Margin (2020 - 2025)
Ovid Therapeutics' (OVID) quarterly EBT Margin came in at 1345.82% in Q4 2025, up 1352082.0% YoY from N/an in Q4 2024, and up 114.61% on a QoQ basis from 9210.61% in Q3 2025.
Ovid Therapeutics (OVID) EBT Margin (2020 - 2025) Analysis & Trends
Ovid Therapeutics (OVID) has 6 years of EBT Margin data on file, last reported at 1345.82% in Q4 2025.
- Quarterly EBT Margin rose 1352082.0% year-over-year to 1345.82% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 339.33% (up 421779.0% YoY) and the FY2025 annual result came in at 240.13%, up 443001.0% from the prior year.
- EBT Margin climbed to 1345.82% in Q4 2025, from 9210.61% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 5042.01% in Q2 2024 to a low of 107798.33% in Q3 2022.
- A 5-year average of 14407.56% and a median of 8653.28% in 2024 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 9747448 bps in 2023, down 1912536 bps in 2023.
- Tracing OVID's EBT Margin over 5 years: stood at 84.7% in 2021, then sank by 29448 bps to 24859.09% in 2022, then jumped by 57 bps to 10790.14% in 2023, then retreated by 13 bps to 12175.0% in 2024, then jumped by 111 bps to 1345.82% in 2025.
- The last three EBT Margin figures came in at 1345.82% (Q4 2025), 9210.61% (Q3 2025), and 74.68% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,345.82% |
| Sep 30, 2025 | -9,210.61% |
| Jun 30, 2025 | -74.68% |
| Mar 31, 2025 | -7,873.08% |
| Dec 31, 2024 | -12,175.00% |
| Sep 30, 2024 | -8,095.95% |
| Jun 30, 2024 | 5,042.01% |
| Mar 31, 2024 | -7,901.35% |
| Dec 31, 2023 | -10,790.14% |
| Sep 30, 2023 | -10,323.85% |
| Jun 30, 2023 | -16,544.00% |
| Mar 31, 2023 | -20,236.36% |
| Dec 31, 2022 | -24,859.09% |
| Sep 30, 2022 | -107,798.33% |
| Mar 31, 2022 | -1,111.00% |
| Mar 31, 2021 | 84.70% |
| Dec 31, 2020 | -386.27% |
| Sep 30, 2020 | -237.56% |